Fragile X Syndrome is the single largest cause of genetically inherited disability amongst diseasescategorised within the autism spectrum disorders.This proposal will aim to develop a new treatment for Fragile X syndrome, called SOL101, which willtreat the underlying cause of the disease rather than the symptoms. SOL101 has already demonstratedproof of concept in pre-clinical disease models and the proposal will develop it to the start of clinicaltrials.As well as the healthcare benefits to the patiens, in terms of alleviation of symptoms, both neurologicaland physical, the cost savings in terms of reduced needs for ongoing care and education assistance willbe considerable.Finance summary table
Interagency Autism Coordinating Committee (IACC)
Autism Research Database (AFD)
